NUVB — Nuvation Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $2.89bn
- $2.54bn
- $7.87m
Annual cashflow statement for Nuvation Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.7 | -86.8 | -104 | -75.8 | -568 |
| Depreciation | |||||
| Non-Cash Items | 2.92 | 13.7 | 11.3 | 7.04 | 449 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.11 | 4.79 | -3.45 | 0.54 | -12.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -36.5 | -68.2 | -96.1 | -68 | -130 |
| Capital Expenditures | -0.145 | -0.282 | -0.37 | -0.069 | -0.162 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -70.2 | -454 | 63.8 | 8.99 | 123 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -70.3 | -455 | 63.5 | 8.92 | 123 |
| Financing Cash Flow Items | -2.52 | 625 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 133 | 626 | 1.33 | 0.628 | 0.331 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26.3 | 103 | -31.3 | -58.5 | -6.93 |